VKTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VKTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2024-05-05), Viking Therapeutics's Intrinsic Value: Projected FCF is $3.68. The stock price of Viking Therapeutics is $76.97. Therefore, Viking Therapeutics's Price-to-Intrinsic-Value-Projected-FCF of today is 20.9.
The historical rank and industry rank for Viking Therapeutics's Intrinsic Value: Projected FCF or its related term are showing as below:
During the past 12 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Viking Therapeutics was 22.28. The lowest was 3.63. And the median was 5.31.
The historical data trend for Viking Therapeutics's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viking Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Intrinsic Value: Projected FCF | Get a 7-Day Free Trial | 1.39 | 0.59 | -0.72 | -2.03 | -0.85 |
Viking Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Intrinsic Value: Projected FCF | Get a 7-Day Free Trial | -2.53 | -0.09 | -0.47 | -0.85 | 3.68 |
For the Biotechnology subindustry, Viking Therapeutics's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Viking Therapeutics's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Viking Therapeutics's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)
In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):
Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)
Add all the Free Cash Flow together and divide 6 will get Viking Therapeutics's Free Cash Flow(6 year avg) = $-38.52.
Viking Therapeutics's Intrinsic Value: Projected FCF for today is calculated as
Intrinsic Value: Projected FCF | = | (Growth Multiple | * | Free Cash Flow (6 year avg) | + | Total Stockholders Equity (Mar24) | * | 0.8) | / | Shares Outstanding (Diluted Average) |
= | (9.5203515959648 | * | -38.52432 | + | 933.892 | * | 0.8) | / | 103.457 | |
= | 3.68 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viking Therapeutics (NAS:VKTX) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Viking Therapeutics's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF | = | Share Price | / | Intrinsic Value: Projected FCF |
= | 76.97 | / | 3.6763924007514 | |
= | 20.94 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Viking Therapeutics's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Sarah Kathryn Rouan | director | 4995 BRADENTON AVENUE, SUITE 240, DUBLIN OH 43017 |
Greg Zante | officer: Chief Financial Officer | C/O SANGAMO BIOSCIENCES, INC STE-A-100, POINT RICHMOND TECH, 501 CANAL BLVD,, RICHMOND CA 94804 |
Rowland Charles A Jr | director | 3338 LANCASHIRE RD, FURLONG PA 18925 |
Lawson Macartney | director | C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037 |
Brian Lian | director, officer: President & CEO | C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022 |
Marianna Mancini | officer: Chief Operating Officer | C/O VIKING THERAPEUTICS, INC., 12340 EL CAMINO REAL, STE 250, SAN DIEGO CA 92130 |
Matthew W Foehr | director | 11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037 |
Ligand Pharmaceuticals Inc | 10 percent owner | 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO CA 92121 |
Hiroko Masamune | officer: Chief Development Officer | C/O VIKING THERAPEUTICS, INC., 12340 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130 |
Michael Morneau | officer: Chief Financial Officer | C/O TRIUS THERAPEUTICS, INC., 6410 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121 |
J Matthew Singleton | director | 286 STANWICH ROAD, GREENWICH CT 06830 |
Stephen W Webster | director | C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, SAN DIEGO CA 07302 |
Rochelle Hanley | officer: Chief Medical Officer | C/O VIKING THERAPEUTICS, INC., 11119 NORTH TORREY PINES ROAD, SUITE 50, SAN DIEGO CA 92037 |
Michael Dinerman | officer: Chief Operating Officer | C/O VIKING THERAPEUTICS, INC., 11119 NORTH TORREY PINES ROAD, SUITE 50, SAN DIEGO CA 92037 |
From GuruFocus
By PRNewswire PRNewswire • 03-30-2023
By PRNewswire PRNewswire • 02-01-2023
By PRNewswire PRNewswire • 02-07-2023
By PRNewswire PRNewswire • 05-16-2023
By GuruFocus Research • 01-05-2024
By PRNewswire PRNewswire • 04-26-2023
By PRNewswire • 12-04-2023
By GuruFocus Research • 01-20-2024
By PRNewswire • 07-26-2023
By GuruFocus Research • 10-25-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.